ASH 2016 | Dr Moorman’s highlights on mixed phenotype acute leukemia (MPAL) from ASH 2016
Anthony Moorman, PhD from Newcastle University, Newcastle, UK provides highlights from the the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA. Dr Moorman describes an international study conducted at St. Jude Children’s hospital which looked into the treatment of mixed phenotype acute leukemia (MPAL). For many years it has been unknown as to how patients with MPAL should be treated due to the mixed disease phenotype, in this study they were able to identify sub-sets of patients which will help in both the diagnosis and treatment of MPAL patients. Dr Moorman continues to discuss another international study on MPAL which profiled 100 MPAL patients, this study yielded insight into how best to diagnose patients in order to chose the best treatment for them. This video has been supported by Incyte through an unrestricted educational grant.
